Ocera Therapeutics, Inc.

Biotechnology ResearchCalifornia, United States11-50 Employees

Ocera Therapeutics (NASDAQ:OCRX) is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with serious diseases in areas of high unmet medical need. Ocera’s lead drug candidate OCR-002 is a novel ammonia scavenger which rapidly removes ammonia from the blood. Elevated ammonia is believed to be one of the primary causes of hepatic encephalopathy (HE). OCR-002 is the subject of STOP-HE, a Company-sponsored Phase 2b trial, and two investigator-sponsored Phase 2a trials. OCR-002 has received Orphan Drug designation in both the U.S. and Europe and has been granted Fast Track status by the U.S. Food and Drug Administration.

Sign up for free to view info

Email Format Employee directory